Drug intelligence / Profile preview

HP01

Development stage: Preclinical
Lead developer: Hanpoong Pharm
Administration: Oral

Overview

HP01 is a Vitis labrusca extract derived from the leaves of the Vitis labrusca plant. It has demonstrated potent antioxidant activity, improved blood circulation by modulating the extrinsic clotting pathway and inhibiting platelet aggregation, and ameliorated lipid metabolism disorders by reducing hepatic triglyceride and total cholesterol accumulation in hyperlipidemic rat models. These actions collectively contribute to its observed hepatoprotective effects, including the reduction of elevated alanine aminotransferase (ALT) levels. HP01 is being investigated for its potential as a functional food or therapeutic agent for the prevention and treatment of hyperlipidemia and cardiovascular disease risk factors.

Other names: Vitis labrusca ExtractV. labrusca extract

Targets

F (Coagulation factors)NPC1L1 (Niemann-pick C1-Like 1 transporter)

Beyond the preview

Go deeper on HP01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HP01.

Explore the full profile